This map shows the geographic impact of Newell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Newell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Newell more than expected).
This network shows the impact of papers produced by Newell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Newell. The network helps show where Newell may publish in the future.
Co-authorship network of co-authors of Newell
This figure shows the co-authorship network connecting the top 25 collaborators of Newell.
A scholar is included among the top collaborators of Newell based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Newell. Newell is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Newell, et al.. (2014). The Evaluation of Homer as a Marine Corps Expeditionary Energy Pre-Deployment Tool.2 indexed citations
3.
Bärnighausen, Till, et al.. (2010). HIV Incidence Estimation Using the BED Capture Enzyme Immunoassay : Systematic Review and Sensitivity Analysis.. Epidemiology.2 indexed citations
4.
Plummer, E. Ruth, Mark R. Middleton, R. Wilson, et al.. (2005). Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide. Clinical Cancer Research. 11.6 indexed citations
5.
Davies, T. G. E., J. Bentley, AH Calvert, et al.. (2001). Structural and thermodynamic validation of inactive cdk2 as a template for structure-based drug design. Cellular & Molecular Biology Letters. 6. 514–515.1 indexed citations
6.
Curtin, Nicola J., Suzanne Kyle, Robert Griffin, et al.. (2000). Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase. Clinical Cancer Research.1 indexed citations
Boddy, Alan V., CR Pinkerton, Ian Lewis, et al.. (1998). Validation of pharmacologically-guided dosing of carboplatin in paediatric patients. British Journal of Cancer. 78. 9–9.2 indexed citations
12.
Bailey, et al.. (1995). Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridplthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion. Clinical Cancer Research.10 indexed citations
13.
Price, et al.. (1994). The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in pediatric patients: A review.. Anticancer Research.2 indexed citations
14.
Calvert, A H, Newell, A.L. Jackman, et al.. (1987). Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).. PubMed. 213–8.25 indexed citations
15.
Newell, et al.. (1986). Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse.. PubMed. 70(8). 971–9.22 indexed citations
16.
Newell, et al.. (1985). DIPYRIDAMOLE INDUCED-INHIBITION OF THYMIDINE INCORPORATION INVIVO AND POTENTIATION OF CB3717 CYTO-TOXICITY INVITRO. British Journal of Cancer.2 indexed citations
17.
Newell, et al.. (1983). PHARMACOKINETIC STUDIES IN HUMANS WITH CB3717 (N-(4-(2-AMINO-4-HYDROXY-6-QUINAZOLINYL)METHYL)PROP-2-YNYLAMINO)BENZOYL)-L-GLUTAMIC ACID). UCL Discovery (University College London).1 indexed citations
18.
Jackman, A.L., et al.. (1982). BIOCHEMICAL DISTURBANCES OBSERVED INVITRO AND INVIVO FOLLOWING INHIBITION OF THYMIDYLATE SYNTHETASE BY C-3717. UCL Discovery (University College London).1 indexed citations
19.
Newell, et al.. (1981). Persuasion In Marketing: The Dynamics Of Marketing's Great Untapped Resource.4 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.